Multiple-tumor aberrant growth genes

Abstract

The invention relates to the multi-tumor aberrant growth gene having the nucleotide sequence of any one of the strands of any one of the members of the High Mobility Group protein genes or LIM protein genes, including modified versions and derivatives thereof. The gene and its derivatives may be used in various diagnostic and therapeutic applications.

1 . A method for treating cells having a non-physiological proliferative capacity or macromolecules derived therefrom comprising contacting the cells or macromolecules with a nucleic acid substantially corresponding to or complementary to the HMGI-C gene, a derivative of the gene or a modulator of expression of the gene. 
     
     
         2 . The method as claimed in  claim 1 , further comprising a method for treating cells having a non-physiological proliferative capacity and including the step of contacting said cells with a nucleic acid substantially corresponding to or complementary to the HMGI-C gene, a derivative of the gene, or a modulator of expression of the gene. 
     
     
         3 . The method as claimed in  claim 1 , wherein said nucleic acid comprises a derivative of a multi-tumor aberrant growth gene, wherein the derivative is a nucleic acid substantially corresponding to a truncated version of the HMGI-C gene selected from the group consisting of:
 a) exons 1, 2 and 3 and truncated in intron 3 after nucleotide sequence TAGGAAATGG (SEQ ID NO: 103);   b) exons 1, 2, 3 and 4 and truncated in intron 4 after nucleotide sequence GCCTGCTCAG (SEQ ID NO: 134); and   c) a complete coding sequence of HMGI-C and truncated in the 3′ untranslated region after one of the sequences:   
       
         
           
                 
                 
                 
               
                     
                   TATCCTTTCA 
                   (SEQ ID NO: 135) 
                 
                     
                     
                 
                     
                   TCTTTCCACT 
                   (SEQ ID NO: 136) 
                 
                     
                     
                 
                     
                   ATACCACTTA 
                   (SEQ ID NO: 137) 
                 
                     
                     
                 
                     
                   TTGCCATGGT 
                   (SEQ ID NO: 138) 
                 
                     
                     
                 
                     
                   CACTTTCATC 
                   (SEQ ID NO: 139) 
                 
                     
                     
                 
                     
                   ATAAGGACTA 
                   (SEQ ID NO: 140) 
                 
                     
                     
                 
                     
                   NCTTGTNAGC. 
                   (SEQ ID NO: 141) 
                 
             
                
                
                
                
                
                
                
                
                
                
                
                
                
               
            
           
         
       
     
     
         4 . A macromolecule for incorporation in a therapeutic composition for cancer treatment, comprising a derivative of a multi-tumor aberrant growth gene, wherein the derivative is a nucleic acid substantially corresponding to a truncated version of the HMGI-C gene selected from the group consisting of:
 a) exons 1, 2 and 3 and truncated in intron 3 after nucleotide sequence TAGGAAATGG (SEQ ID NO: 103);   b) exons 1, 2, 3 and 4 and truncated in intron 4 after nucleotide sequence GCCTGCTCAG (SEQ ID NO: 134); and   c) a complete coding sequence of HMGI-C and truncated in the 3′ untranslated region after one of the sequences:   
       
         
           
                 
                 
                 
               
                     
                   TATCCTTTCA 
                   (SEQ ID NO: 135) 
                 
                     
                     
                 
                     
                   TCTTTCCACT 
                   (SEQ ID NO: 136) 
                 
                     
                     
                 
                     
                   ATACCACTTA 
                   (SEQ ID NO: 137) 
                 
                     
                     
                 
                     
                   TTGCCATGGT 
                   (SEQ ID NO: 138) 
                 
                     
                     
                 
                     
                   CACTTTCATC 
                   (SEQ ID NO: 139) 
                 
                     
                     
                 
                     
                   ATAAGGACTA 
                   (SEQ ID NO: 140) 
                 
                     
                     
                 
                     
                   NCTTGTNAGC. 
                   (SEQ ID NO: 141) 
                 
             
                
                
                
                
                
                
                
                
                
                
                
                
                
               
            
           
         
       
     
     
         5 . The macromolecule as claimed in  claim 4 , wherein the derivative comprises a hybrid of the truncated version of the HMGI-C gene and its translocation partner, and the 5′ end of the translocation partner is identifiable by one of a sequence selected from the group consisting of SEQ ID NOs: 104-133 and 142-159. 
     
     
         6 . The method as claimed in  claim 1 , wherein the complementary nucleic acid is an anti-sense molecule.